Group 1 - Heng Rui Medicine's HRS-5346 tablets have been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [30][30] - Yuguang Jin Lead announced a significant short-term stock price increase of 45.01% over five consecutive trading days, raising concerns about the uncertainty of future silver prices [31] - Dongcai Technology's actual controller and vice chairman has been detained and investigated, but the company states that this will not significantly impact its normal operations [32] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [33] - Jingpin Special Equipment has been banned from participating in procurement activities for the armed police force for three years, which will have a limited impact on its overall revenue [34] - Nanhua Futures' overseas subsidiary has obtained membership approval for the Nodal Exchange, allowing it to trade and clear related products [35] Group 3 - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss of 299 million yuan in the previous year due to market recovery and operational improvements [38] - Deep South Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by growth in AI computing power and storage market demand [39] - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from a loss of 954 million yuan the previous year [40] Group 4 - Nanya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to the recovery in the copper-clad laminate industry [41] - CanSino Biologics expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [42] - Zhiguang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a loss of 326 million yuan due to rapid growth in its energy storage business [43] Group 5 - Dongfang Securities expects a net profit increase of 67.8% in 2025, supported by growth in its core investment banking and wealth management businesses [44] - King Long Motors forecasts a net profit of approximately 463.26 million yuan in 2025, reflecting a 193.68% increase due to steady growth in overseas markets [45] - Zhenray Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits and satellite communication markets [46] Group 6 - Yongding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, representing an increase of 225.66% to 388.48% due to investment income from its joint ventures [47] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase driven by rising prices of tungsten and rare earth materials [48] - Guodun Quantum expects to achieve a net profit of around 5 million yuan in 2025, reversing a loss from the previous year due to growth in the quantum computing sector [49] Group 7 - Shijia Photon anticipates a net profit of approximately 342 million yuan in 2025, reflecting a growth of around 426% due to increased orders in optical chips and cables [50] - Ningbo Fubang expects a net profit of 50 million to 70 million yuan in 2025, with a significant increase of 3099.59% to 4379.43% driven by rising silver prices and non-recurring gains [51] - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share, reflecting confidence in its future development [52]

证券日报网讯1月27日，恒瑞医药（600276）发布公告称，2026年1月份，公司通过上海证券交易所交易 系统以集中竞价交易方式回购股份17.5万股，占公司总股本的比例为0.003%。截至2026年1月27日，公 司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式累计回购股份907.37万股， 占公司总股本的比例为0.14%。 ...

Core Viewpoint - The healthcare index (980016) closed at 6173.05 points, down 0.98%, with a trading volume of 32.835 billion yuan and a turnover rate of 1.29% [1] Group 1: Index Performance - Among the index constituents, 11 stocks rose while 39 stocks fell, with Sangfor Technologies leading the gainers at a 10.93% increase and Huahai Pharmaceutical leading the decliners with a 3.79% drop [1] - The top ten constituents of the healthcare index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 10.23%, 9.85%, and 8.23% [1] Group 2: Market Capitalization and Price Movements - WuXi AppTec has a market capitalization of 285.814 billion yuan, while Hengrui Medicine and Mindray Medical have market capitalizations of 379.648 billion yuan and 232.983 billion yuan, respectively [1] - The latest prices for the top ten constituents range from 11.12 yuan for Aier Eye Hospital to 192.16 yuan for Mindray Medical, with varying price changes [1] Group 3: Capital Flow - The net outflow of main funds from the healthcare index constituents totaled 1.252 billion yuan, while retail investors saw a net inflow of 1.093 billion yuan [1] - Detailed capital flow data indicates that Junshi Biosciences experienced a net inflow of 1.93 million yuan from main funds, while other companies like Dong'e Ejiao and Tigermed saw mixed capital flows [2]

Group 1 - Heng Rui Medicine's HRS-5346 tablet has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [2] - Yu Guang Jin Lead announced a significant stock price increase of 45.01% over five trading days, expressing uncertainty about the future price of silver [3] - Dongcai Technology's actual controller and vice chairman has been detained for investigation, but the company states that this will not significantly impact its normal operations [4] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [5] - Jingpin Special Equipment has been banned from participating in procurement activities for three years, but the impact on overall operations is considered limited [6] - Nanhua Futures' overseas subsidiary has obtained membership at the Nodal Exchange, allowing it to trade and clear related products [7] Group 3 - Di'er Laser is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy [8] - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss from the previous year due to market improvements [10] - Shen Nan Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by demand in AI computing and smart automotive sectors [11] Group 4 - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from the previous year's loss [12] - Nan Ya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to a recovery in the copper-clad laminate industry [13] - CanSino expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [14] Group 5 - Zhi Guang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a previous loss due to growth in its energy storage business [15] - Dongfang Securities expects a net profit increase of 67.8% in 2025, benefiting from capital market opportunities [17] - Jinlong Automobile forecasts a net profit increase of 193.68% in 2025, supported by growth in overseas markets [18] Group 6 - Zhen Lei Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits [19] - Yong Ding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, reflecting significant growth from investment income [20] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase year-on-year [21] Group 7 - Guo Dun Quantum expects a net profit of 5 million yuan in 2025, marking a return to profitability [22] - Shi Jia Photon forecasts a net profit increase of approximately 426% in 2025, driven by growth in optical chip orders [23] - Ningbo Fubang anticipates a net profit increase of 3099.59% to 4379.43% in 2025, largely due to rising silver prices and significant non-recurring gains [24] Group 8 - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share [26] - Aonong Biological announced plans for multiple shareholders to reduce their stakes [28] - Pizaihuang's controlling shareholder intends to increase its stake by 300 million to 500 million yuan [29]

脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱的典型表现之一。中国成年人 的Lp(a)水平>30mg/dL和50mg/dL的患病率分别为18.67%和8.41%。高Lp(a)已被证实为动脉粥样硬化性 心血管疾病包括冠心病、缺血性脑卒中、外围血管疾病及钙化性主动脉瓣狭窄等疾病的独立危险因素 [2]。靶向Lp(a)的降脂疗法是心血管疾病防治的重要突破方向之一。HRS-5346是一种Lp(a)口服小分子抑 制剂，经查询，目前国内外尚无同类产品获批上市。截至目前，HRS-5346片相关项目累计研发投入约 为7630万元(未经审计)。 根据《国家药监局关于发布 <突破性治疗药物审评工作程序 试行="试行"> 等三个文件的公告》(2020年 第82号)，药审中心对纳入突破性治疗药物程序的药物优先配置资源进行沟通交流，加强指导并促进药 物研发。药品研发容易受到技术、审批、政策等多方面因素的影响，审评政策及未来药品市场竞争形势 等存在诸多不确定性风险。 恒瑞医药（600276）(01276)发布公告，近日,江苏恒瑞医药股份有限公司(以下简称"公司")子公司山东盛 迪医药有限公司的HRS-5346 ...

智通财经APP讯，恒瑞医药(01276)发布公告，近日,江苏恒瑞医药股份有限公司(以下简称"公司")子公司 山东盛迪医药有限公司的HRS-5346片被国家药品监督管理局药品审评中心(以下简称"药审中心")纳入突 破性治疗品种名单。 根据《国家药监局关于发布<突破性治疗药物审评工作程序(试行)>等三个文件的公告》(2020年第82 号)，药审中心对纳入突破性治疗药物程序的药物优先配置资源进行沟通交流，加强指导并促进药物研 发。药品研发容易受到技术、审批、政策等多方面因素的影响，审评政策及未来药品市场竞争形势等存 在诸多不确定性风险。 脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱的典型表现之一。中国成年人 的Lp(a)水平>30mg/dL和50mg/dL的患病率分别为 18.67%和8.41% 。高Lp(a)已被证实为动脉粥样硬化性 心血管疾病包括冠心病、缺血性脑卒中、外围血管疾病及钙化性主动脉瓣狭窄等疾病的独立危险因素 [2]。靶向 Lp(a)的降脂疗法是心血管疾病防治的重要突破方向之一。HRS-5346是一种Lp(a)口服小分子 抑制剂，经查询，目前国内外尚无同类产品获批上市。 ...

脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱的典型表现之一。中国成年人 的Lp(a)水平＞30mg/dL和50mg/dL的患病率分别为18.67%和8.41%[1]。高Lp(a)已被证实为动脉粥样硬化 性心血管疾病包括冠心病、缺血性脑卒中、外围血管疾病及钙化性主动脉瓣狭窄等疾病的独立危险因素 [2]。靶向Lp(a)的降脂疗法是心血管疾病防治的重要突破方向之一。HRS-5346是一种Lp(a)口服小分子抑 制剂，经查询，目前国内外尚无同类产品获批上市。截至目前，HRS-5346片相关项目累计研发投入约 为7,630万元(未经审计)。 格隆汇1月27日丨恒瑞医药(01276.HK)公告，近日,江苏恒瑞医药股份有限公司(以下简称"公司")子公司 山东盛迪医药有限公司的HRS-5346片被国家药品监督管理局药品审评中心(以下简称"药审中心")纳入突 破性治疗品种名单。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月27日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-013 ...

截至2026年1月27日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回 购股份907.37万股，已回购股份占公司总股本的比例为0.14%，购买的最高价为人民币70.00元/股，最低 价为人民币57.20元/股，已支付的总金额为人民币6.05亿元(不含交易费用)。 智通财经APP讯，恒瑞医药(01276)发布公告，江苏恒瑞医药股份有限公司(以下简称"公司")于2025年8 月20日召开第九届董事会第十八次会议审议通过了《关于以集中竞价交易方式回购公司A股股份方案的 议案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实施A股员工持股计划。回购 价格不超过人民币90.85元/股(含)，回购资金总额不低于人民币10亿元且不超过20亿元。回购期限为自 董事会审议通过回购股份方案之日起12个月以内。 2026年1月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份17.5万股，已回购股份占 公司总股本的比例为0.003%，购买的最高价为人民币57.48元/股，最低价为人民币57.20元/股，已支付 的总金额为人民币1003.86万元(不含交易费用)。 ...

2026年1月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份17.5万股，已回购股份占 公司总股本的比例为0.003%，购买的最高价为人民币57.48元/股，最低价为人民币57.20元/股，已支付 的总金额为人民币1003.86万元(不含交易费用)。 恒瑞医药（600276）(01276)发布公告，江苏恒瑞医药股份有限公司(以下简称"公司")于2025年8月20日 召开第九届董事会第十八次会议审议通过了《关于以集中竞价交易方式回购公司A股股份方案的议 案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实施A股员工持股计划。回购价 格不超过人民币90.85元/股(含)，回购资金总额不低于人民币10亿元且不超过20亿元。回购期限为自董 事会审议通过回购股份方案之日起12个月以内。 截至2026年1月27日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回 购股份907.37万股，已回购股份占公司总股本的比例为0.14%，购买的最高价为人民币70.00元/股，最低 价为人民币57.20元/股，已支付的总金额为人民币6.05亿元(不含交易费用)。 ...